Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BMRN
BIOMARIN PHARMACEUTICAL INC.
NASDAQ
$64.67
▼ DOWN 0.96% (-0.63)

KEY STATISTICS

Market Cap$12.50 B
52w High$70.98
52w Low$49.26
Dividend Yield—
Frequency—
P/E31.09
Volume1.10M
Shares Out.193.28M

COMPANY

LEADERSHIP

Alexander Hardy
CHIEF EXECUTIVE
Alexander Hardy

COMPENSATION 2026

Salary$1,130,769
Stock Awards$16,833,629
Incentive Plan Pay$1,644,500
All Other Comp.$409,355
Total$21,927,563

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 26, 1999
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
3,221

PRICE TARGET

Target High$124.00
Target Low$59.00
Target Median$97.00
Target Consensus$91.59

UPCOMING EARNINGS

DateOct 26, 2026
DayMonday
Rev. Est.$1.03B
OCT
26
MON

PRICE

$64.67 ▼ DOWN 0.96% (−$0.63)
$64.20$64.50$64.80$65.109:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM64.67

About BioMarin Pharmaceutical Inc.

https://www.biomarin.com ↗

BioMarin develops and commercializes therapies for rare diseases, including enzyme replacements, gene therapies, and treatments for conditions like MPS, PKU, and hemophilia, serving global markets through collaborations and specialty distribution.

INDUSTRY

Biotechnology

A PRODUCT BIOMARIN PHARMACEUTICAL INC. IS KNOWN FOR

Voxzogo (vosoritide)
Voxzogo (vosoritide)

Voxzogo is a daily injection approved for increasing growth in children with achondroplasia, driving BioMarin's revenue growth through strong market adoption and strategic commercial focus.

COMPETITORS

COMPETITOR
ALNY COMPARE
ASND COMPARE
BBIO COMPARE
RARE COMPARE
SRPT COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$760.81M $859.32M ▲$760.08M ▼$984.39M ▲
Royalty And Other$15.32M $15.24M ▼$6.13M ▼$5.32M ▼

Revenue by Geography

MapREGIONQ4-2020Q1-2021Q2-2021Q3-2021
UNITED STATES$182.7M $208.19M ▲$204.25M ▼$196.24M ▼
Europe$143.01M $161.84M ▲$172.68M ▲$115.5M ▼
Rest Of World$62.39M $56.3M ▼$82.52M ▲$58.05M ▼
Latin America$64.01M $59.7M ▼$42.25M ▼$38.96M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
328
LISTED HERE
26
RANKED BY POSITION SIZE
XAW.TO
0.01% · 6.8M
VTI
0.02% · 6.2M
XBI
1.03% · 1.9M
FBT
3.34% · 1.5M
SCHM
0.23% · 534.8K
SZNE
1.47% · 510.8K
DFSV
0.35% · 452.0K
FMDE
0.29% · 371.8K
DSTL
0.72% · 233.4K
PBE
2.79% · 174.1K
JHMM
0.17% · 160.1K
SFLO
0.87% · 106.5K
JMEE
0.23% · 104.8K
BBH
1.28% · 94.4K
SP5C.L
0.02% · 85.7K
LABU
0.70% · 68.5K
DOCT.L
1.26% · 63.7K
XHYH
0.69% · 55.0K
GNOM
3.45% · 50.4K
PB
PBPH
0.27% · 43.7K
AVUS
0.02% · 42.6K
SRHQ
1.20% · 41.4K
EZM
0.28% · 40.2K
BKMC
0.31% · 31.4K
JOET
0.82% · 31.2K
IQSM
0.46% · 24.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
73.35%
HOLDERS
980
TOP 12 OF 980 · RANKED BY POSITION SIZE
Blackrock Inc.
22.7M sh · $1.87B
Blackrock, Inc.
22.0M sh · $1.19B
Vanguard Group Inc
18.6M sh · $1.01B
Primecap Management Co/Ca/
15.2M sh · $824.82M
Dodge & Cox
14.8M sh · $849.43M
State Street Corp
8.8M sh · $474.69M
Viking Global Investors LP
8.3M sh · $450.73M
Norges Bank
8.2M sh · $469.66M
Aqr Capital Management LLC
7.7M sh · $429.35M
Vestal Point Capital, LP
6.0M sh · $344.75M
Fmr LLC
4.8M sh · $275.97M
Citadel Advisors LLC
4.5M sh · $254.92M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity3
Return On Assets3
Debt To Equity2
Price To Earnings1
Price To Book3
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Ro Khanna
Ro Khanna
Sale
2023-03-14
 Daniel Goldman
Daniel Goldman
Sale (Full)
2023-03-06
 Josh Gottheimer
Josh Gottheimer
Sale (Full)
2021-10-18
 Gilbert Cisneros
Gilbert Cisneros
Purchase
2020-12-30

INSIDER TRADES

★
DIRECTOR
Enyedy Mark J
Purchase · 7.5K shares
2026-06-02
★
DIRECTOR
CLARK IAN T
Purchase · 7.5K shares
2026-06-02
★
DIRECTOR
Bodem Barbara W.
Purchase · 7.5K shares
2026-06-02
★
DIRECTOR
ANDERSON ELIZABETH M
Purchase · 7.5K shares
2026-06-02

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OVERWEIGHT 5
OUTPERFORM 4
NEUTRAL 1
SECTOR PERFORM 1
MARKET PERFORM 1
HOLD 1
19 GRADES IN THE LAST 12 MONTHS
BMO Capital OUTPERFORM HC Wainwright & Co. NEUTRAL Barclays OVERWEIGHT Piper Sandler OVERWEIGHT Canaccord Genuity BUY Morgan Stanley OVERWEIGHT Oppenheimer OUTPERFORM Citigroup BUY

SECTORS PEERS

PEERPRICE
MRNA$137.99COMPARE
RVMD$207.88COMPARE
BBIO$76.60COMPARE
EXEL$54.45COMPARE
HALO$105.35COMPARE
MDGL$533.76COMPARE
TECH$72.35COMPARE
ALGN$157.58COMPARE